pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Hypertriglyceridemia
drug · oligonucleotide
save

Hypertriglyceridemia

pre_registrationupdated 6mo ago
by LP Pharmaceutical (Xiamen) Co Ltd🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 6
  • drugObesity1 co-mentions · 1 sources
  • companySiddhakala Ayurvedik Medical College1 co-mentions · 1 sources
  • tagEndocrinology & Metabolism1 co-mentions · 1 sources
  • tagHepatology1 co-mentions · 1 sources
  • tagObesity1 co-mentions · 1 sources
  • drugayurvedic medicine1 co-mentions · 1 sources

Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

targets

Apolipoprotein C-III mRNA 3'UTR

all catalysts(0)

nothing on the calendar yet

News(10)

  • Cellectis could cut 70% of workforce in shift to in vivo therapies
    Cellectis’ business transformation could cost around 160 global employees their jobs. The company has stopped enrollment in its two CAR T programs as it focuses on trials of its in vivo candidates.
    biospace · 3d ago
  • Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
    When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
    biospace · 3d ago
  • Cellectis will shed 70% of workforce as part of in vivo pivot
    Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
    fiercebiotech · 4d ago
  • #AHA26: Marea’s triglyceride candidate could have an edge in diabetic patients
    Marea Therapeutics' investigational lipid-lowering medicine has shown further promise in cutting triglycerides in patients with dangerously high levels of these fatty molecules in their blood. It a…
    endpoints · 7d ago
  • Recent Lisata prize Marea touts ‘exciting’ lipid disorder phase 2 win, mulls obesity potential
    Fresh from a merger with oncology drugmaker Lisata Therapeutics, cardiometabolic biotech Marea Therapeutics has revealed results from the first part of a phase 2b study showing its drug candidate M…
    fiercebiotech · 11d ago
  • GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatment
    Hibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug ap…
    biospace · 26d ago
  • On the move: 4 rare disease companies hiring now
    Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.
    biospace · 1mo ago
  • Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
    A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay…
    biospace · 1mo ago
  • Lisata deal propels Marea’s drug pipeline to Wall Street
    Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.
    biopharma_dive · 2mo ago
  • After one failed acquisition attempt, Lisata finds lifeline in Marea merger
    After a failed merger that led to massive layoffs and a lawsuit, solid tumor biotech Lisata Therapeutics has found a new future through a merger with cardio specialist Marea Therapeutics.
    fiercebiotech · 2mo ago
view all news mentions →
MOA
Apolipoprotein C-III mRNA 3'UTR antisense inhibitor
indication
Hypertriglyceridemia
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?